ABBV-066
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin(IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23.
Analyst Outlook
ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) has demonstrated iomising clinical performance to date, outperforming the first-to-market interleukin (IL)-12/23 inhibitor Stelara (ustekinumab; Johnson & Johnson) in its Phase II study. In spite of this, however, Datamonitor Healthcare believes that its anticipated late market entry behind the two other late-phase IL-23 inhibitors, guselkumab (Johnson & Johnson/MorphoSys) and tildrakizumab (Merck & Co/Sun Pharma), will restrict its patient share, even in light of AbbVie’s extensive experience in autoimmune indications. Once approved and launched, ABBV-066 is expected to be used late in the psoriasis treatment algorithm, targeting patients who have failed treatment with the well-established anti-tumor necrosis factor (TNF) biologics and/or the marketed IL inhibitors.ce
EXECUTIVE SUMMARY……………………………………………………………. ES-1
i. Clinical Overview of Neurovascular Disease ……………………………. ES-1
a. Arteriovenous Malformations………………………………………………….. ES-1
b. Brain Aneurysms …………………………………………………………………… ES-2
c. Stroke………………………………………………………………………………………. ES-2
ii. US Neurointerventional Devices Market………………………………… ES-3
iii. Market Forecasts, by Segment………………………………………………. ES-4
iv. Methodology………………………………………………………………………….. ES-6
Exhibit ES-1: US Neurointerventional Devices Market Forecast,
by Therapy Segment ($m), 2015–20 ………………………………………. ES-7
Exhibit ES-2: US Neurointerventional Devices Market, Estimated
Percentage of Sales, by Type of Therapy, 2015 ………………………. ES-9
Exhibit ES-3: US Neurointerventional Devices Market, Estimated
Percentage of Sales, by Type of Therapy, 2020 …………………….. ES-10
1. CEREBRAL ANEURYSM AND AVM EMBOLIZATION SYSTEMS
MARKET…………………………………………………………………………….. 1-1
1.1 Microcoils ……………………………………………………………………… 1-3
1.1.1 Blockade Medical ………………………………………………………… 1-4
1.1.2 Codman Neuro/DePuy Synthes …………………………………. 1-4
1.1.3 Medtronic (Covidien) ………………………………………………… 1-4
1.1.4 MicroVention-Terumo ……………………………………………….. 1-4
1.1.5 Stryker………………………………………………………………………… 1-5
1.2 Liquid Embolics……………………………………………………………. 1-5
1.2.1 Medtronic…………………………………………………………………… 1-7
1.2.2 Codman Neuro/DePuy Synthes ………………………………… 1-7
1.3 The ARUBA Trial………………………………………………………….. 1-8
1.4 Market Forecast……………………………………………………………. 1-9
1.5 Competitive Analysis……………………………………………………… 1-10
Exhibit 1-1: Stryker’s Target Nano and Target 360 Detachable Coils ……………… 1-6
Exhibit 1-2: Cerebral Aneurysm and AVM Endovascular Embolization
Systems Market Forecast, 2015–20 ………………………………………… 1-11
Exhibit 1-3: Cerebral Aneurysm and AVM Endovascular Embolization
Systems Market, Share by Supplier, 2015 ……………………………….. 1-13
2. WIDE-NECK CEREBRAL ANEURYSM EMBOLIZATION-ENABLING STENT SYSTEMS MARKET……………………………………………………………………………………………… 2-1
2.1 Adjuvant Embolic Coil-Containment Stenting Systems ………………… 2-1
2.1.1 Codman Neuro/DePuy Synthes ………………………………………………….. 2-2
2.1.2 Stryker………………………………………………………………………………………… 2-3
2.2 Flow-Diversion Devices…………………………………………………………………. 2-3
2.2.1 Medtronic……………………………………………………………………………………. 2-3
2.2.2 Sequent Medical/MicroVention-Terumo ……………………………………. 2-6
2.2.3 Others………………………………………………………………………………………….. 2-7
2.2.3.1 Acandis GmbH ………………………………………….. 2-7
2.2.3.2 InspireMD ………………………………………………… 2-7
2.2.3.3 MicroVention-Terumo……………………………….. 2-9
2.2.3.4 Phenox GmbH…………………………………………… 2-9
2.2.3.5 Stryker ………………………………………………………. 2-9
2.3 Market Forecast……………………………………………….. 2-9
2.4 Competitive Analysis……………………………………….. 2-13
Exhibit 2-1: Stryker’s Neuroform EZ Stent…………….. 2-4
Exhibit 2-2: Sequent Medical/MicroVention-Terumo’s WEB…………………………… 2-8
Exhibit 2-3: Wide-Neck Cerebral Aneurysm Embolization-Enabling Stent Systems Market Forecast, 2015–20 ………………………………………… 2-11
Exhibit 2-4: Wide-Neck Cerebral Aneurysm Embolization-Enabling Stent
Systems Market, Share by Supplier, 2015 ……………………………………………… 2-14
3. CAROTID ARTERY STENT SYSTEMS MARKET ……………………………….. 3-1
3.1 Carotid Artery Stent Systems …………………………………………………………… 3-1
3.1.1 Abbott Vascular/Abbott Laboratories……………………………………………… 3-2
3.1.2 Boston Scientific…………………………………………………………………………….. 3-4
3.1.3 Cordis/Cardinal Health …………………………………………………………………. 3-4
3.1.4 Medtronic……………………………………………………………………………………….. 3-4
3.1.5 MicroVention-Terumo ……………………………………………………………………. 3-4
3.2 Embolic Protection Systems………………………………………………………………. 3-5
3.2.1 Allium Medical Solutions…………………………………………………………………. 3-7
3.2.2 Cordis/Cardinal Health …………………………………………………………………. 3-8
3.2.3 InspireMD …………………………………………………………………………………….. 3-8
3.2.4 Medtronic………………………………………………………………………………………. 3-9
3.2.5 Silk Road Medical…………………………………………………………………………… 3-9
3.3 CREST Trial Results …………………………………………………………………………. 3-11
3.4 Market Forecast………………………………………………………………………………… 3-14
3.5 Competitive Analysis………………………………………………………………………… 3-17
Exhibit 3-1: Abbott Laboratories’ RX Acculink Carotid Stent System, RX
Accunet and Emboshield NAV6 Embolic Protection Systems ………………… 3-3
Exhibit 3-2: MicroVention-Terumo’s Roadsaver Carotid Artery Stent System…… 3-6
Exhibit 3-3: Medtronic’s SpiderFX………………………………………………………… 3-10
Exhibit 3-4: Carotid Artery Stent Systems, Market Forecast, 2015–20…… 3-16
Exhibit 3-5: Carotid Artery Stent Systems Market, Share by Supplier, 2015 …… 3-18
4. CEREBRAL THROMBECTOMY SYSTEMS MARKET …………………………. 4-1
4.1 Medtronic………………………………………………………………………………. 4-2
4.2 Penumbra……………………………………………………………………………… 4-5
4.3 Stryker………………………………………………………………………………….. 4-6
4.4 Other Emerging Devices ……………………………………………………… 4-9
4.4.1 Acandis GmbH ………………………………………………………………….. 4-9
4.4.2 Codman/Johnson & Johnson ……………………………………………. 4-9
4.4.3 Neuravi …………………………………………………………………………….. 4-10
4.4.4 MicroVention-Terumo ………………………………………………………. 4-10
4.4.5 Phenox GmbH……………………………………………………………………. 4-11
4.5 Selected Clinical Trials…………………………………………………………… 4-11
4.6 2015 AHA/ASA Recommendations for Endovascular Treatment/Mechanical Thrombectomy
…………………………………….. 4-14
4.7 Market Forecast……………………………………………………………………. 4-15
4.8 Competitive Analysis…………………………………………………………… 4-19
Exhibit 4-1: Medtronic’s Solitaire FR Revascularization Device .. 4-3
Exhibit 4-2: Stryker’s Trevo XP ProVue Retriever Featuring a Distal
FlexCell Design ……………………. ……………………………………………………4-8
Exhibit 4-3: Cerebral Thrombectomy Systems Market Forecast, 2015–20 …….. 4-18
Exhibit 4-4: Cerebral Thrombectomy Systems Market, Share by
Supplier, 2015 ……………………………………………………………………………4-20
APPENDIX A: COMPANY LISTING
APPENDIX B: BIBLIOGRAPHY
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Silkis/Vectical 
Sign up to the